Data processing: structural design – modeling – simulation – and em – Simulating nonelectrical device or system – Biological or biochemical
Reexamination Certificate
2006-11-07
2006-11-07
Moran, Marjorie A. (Department: 1631)
Data processing: structural design, modeling, simulation, and em
Simulating nonelectrical device or system
Biological or biochemical
C703S002000, C702S019000
Reexamination Certificate
active
07133814
ABSTRACT:
A system for modeling thrombopoietic lineage in an individual is presented. The system comprises a thrombopoiesis system model including a process progression model, for cells involved in thrombopoiesis, said progression model including multiplication and differentiation. It further comprises a system model modifier, wherein said thrombopoiesis system model is modified by the system model modifier based on parameters specific to the individual. In addition to modifying an individual's thrombopoietic process, the system can be modified to portray different pathological scenarios as well as different scenarios of response to treatment.
REFERENCES:
patent: 5879673 (1999-03-01), Thomas
Kliem et al. A mathematical model of thrombopoiesis in mice. Experimental Hematology. 1997. vol. 25 (8), p. 899.
Wichmann et al. A mathematical model of thrombopoiesis in rats. Cell Tissue Kinetics. 1979. vol. 12 (5), pp. 551-567.
R. Stoffel et al., “Thrombopoietin in Thrombocytopenic Mice: Evidence Against Regulation at the mRNA Level and for a Direct Regulatory Role of Platelets,” The American Society of Hematology, Blood, vol. 87, No. 2, pp. 567-573, Jan. 15, 1996.
Warren S. Alexander, “Thrombopoietin and the c-Mpl receptor: insights from gene targeting,” The International Journal of Biochemistry & Cell Biology, pp. 1027-1035, Jan. 28, 1999.
M. Miyazaki, et al., “The Relationship Between Carboplatin AUC and Serum Thrombopoietin Kinetics in Patients with Lung Cancer,” 2ndDepartment of Internal Medicine, Hiroshima University School of Medicine, Anti Cancer Research, vol. 19, pp. 667-670 (1999).
S. Vadhan-Raj, et al., “Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer,” Annals of Internal Medicine, vol. 126, No. 9, pp. 673-681, May 1997.
H. -E. Wichmann, et al., “A Mathematical Model of Thrombopoiesis in Rats,” Cell Tissue Kinet, vol. 12, pp. 551-567, Jan. 1979.
L. A. Harker, et al., “Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers,” The American Society of Hematology, Blood, vol. 95, No. 8, pp. 2514-2522, Apr. 15, 2000.
H. Mayani, et al., “Lineage Commitment in Human Hemopoiesis Involves Asymmetric Cell Division of Multipotent Progenitors and Does not Appeal to be Influenced by Cytokines,” Journal of Cellular Physiology, vol. 157, pp. 579-586, 1993.
David W. Golde, “The Stem Cell,” Scientific American, pp. 36-43, Dec. 1991.
S. J. Morrison, et al., “The Biology of Hematopoietic Stem Cells,” Annu. Rev. Cell Dev. Biol., vol. 11, pp. 35-71, 1995.
J. Eller, et al., “Modelling Thrombopoiesis Regulation-I; Model Description and Simulation Results,” Comput. Math. Applic., vol. 14, No. 9-12, pp. 841-848, 1987.
G. K. von Schulthess, et al., “Oscillating platelet counts in healthy individuals: Experimental investigation and quantitive evaluation of thrombocytopoietic feedback control,” Scand J Haematol, vol. 36, pp. 473-479, Mar. 8, 1986.
L. A. Harker, et al., “Dose-Response Effects of Pegylated Human Megakaryocyte Growth and Development Factor on Platelet Production and Function in Nonhuman Primates,” The American Society of Hematology, Blood, vol. 88, No. 2, pp. 511-521, Jul. 15, 1996.
P. A. Fielder, “Regulation of Thrombopoietin Levels by c-mpl-Mediated Binding to Platelets,” The American Society of Hematology, Blood, vol. 87, No. 6, pp. 2154-2161, Mar. 15, 1996.
John E. J. Rasko, et al., “Molecules in focus; The thrombopoietic factor, Mpl-ligand,” The International Journal of Biochemistry & Cell Biology, vol. 30, pp. 657-660, 1998.
F. J. de Sauvage, et al., “Physiological Regulation of Early and Late Stages of Megakaryocytopoiesis by Thrombopoietin,” Departments of Molecular Biology, Cell Genetics, vol. 183, pp. 651-656, Feb. 1996.
F. Tacke, et al., “Endogenous serum levels of thrombopoietic cytokines in healthy whole-blood and platelet donors: implications for plateletpheresis,” British Journal of Haematology, vol. 105, pp. 511-513, 1999.
S. A. Burstein, et al., “Megakaryopoiesis and platelet formation,” Williams Hematology, 5thed., Ch. 118, McGraw-Hill, Inc., 1995.
R. Schofield, et al., “Self-Maintenance Capacity of CFU-S,” Journal of Cellular Physiology, vol. 103, pp. 355-362, 1980.
M. Rosendaal, et al., “Organization of Haemopoietic Stem Cells: The Generation-Age Hypothesis,” Cell Tissue Kinet., vol. 12, pp. 17-29, 1979.
A. Iliadis, et al., “Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy-Toxicity Mathematical Model,” Computers and Biomedical Research, vol. 33, pp. 211-226, 2000.
F. L. Pereira, et al., “A new optimization based approach to experimental combination chemotherapy,” Frontiers Med. Biol. Engng., vol. 6, No. 4, pp. 257-268, 1995.
Kenji Terashi, et al., “Close Association between Clearance of Recombinant Human Granulocyte Colony-Stimulating Factor (G-CSF) and G-CSF Receptor on Neutrophils in Cancer Patients,” Antimicrobial Agents and Chemotherapy, vol. 43, No. 1, pp. 21-24, Jan. 1999.
T. H. Price, et al., “Effect of Recombinant Granulocyte Colony-Stimulating Factor on Neutrophil Kenetics in Normal Young and Elderly Humans,” The American Society of Hematology, vol. 88, No. 1, pp. 335-340, Jul. 1, 1996.
B. I. Lord, et al., “The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo,” Proc. Natl. Acad. Sci. USA, vol. 86, pp. 9499-9503, Dec. 1989.
J. Y. Mary, “Normal Human Granulopoiesis Revisited. I. Blood Data, ” Biomedicine & Pharmacotherapy, vol. 38, pp. 33-43, 1984.
J. Y. Mary, “Normal Human Granulopoiesis Revisited. II. Bone Marrow Data, ” Biomedicine & Pharmacotherapy, vol. 38, pp. 66-77, 1984.
C. Dresch, et al., “Growth fraction of myelocytes in normal human granulopoiesis, ” Cell Tissue Kinet. vol. 19, pp. 11-22, 1986.
S. Schmitz, et al., “The effect of continuous G-CSF application in human cyclic neutropenia: a model analysis,” British Journal of Haematology, vol. 90, pp. 41-47, 1995.
S. Schmitz, et al., “Quantification of the cell kinetic effects of G-CSF using a model of human granulopoiesis,” International Society for Experimental Hematology, Experimental Hematology, vol. 21, pp. 755-760, 1993.
L. A. Harker, et al., “Regulation of Platelet Production and Function by Megakaryocyte Growth and Development Factor in Nonhuman Primates,” The American Society of Hematology, No. 5, pp. 1833-1844, Mar. 1996.
Warren S. Alexander, “Thrombopoietin,” The Walter and Eliza Hall Inst. for Medical Research, Growth Factors, vol. 17, pp. 13-24, 1999.
Kenneth Kaushansky, “Thrombopoietin: The Primary Regulator of Platelet Production,” The Journal of The American Society of Hematology, Blood, vol. 86, No. 2, pp. 419-431, Jul. 15, 1995.
Saroj Vadhan-Raj, “Recombinant Human Thrombopoietin: Clinical Experience and In Vivo Biology,” Seminars in Hematology, vol. 35, No. 3, pp. 261-268, Jul. 1998.
Laurence A. Harker, “Physiology and clinical applications of platelet growth factors,” Curr Opin Hematol, vol. 6, pp. 127-134, 1999.
Jack Levin, “Thrombopoietin—Clinically Realized?,” The New England Journal of Medicine, vol. 336, No. 6, pp. 1-3, Feb. 6, 1997.
G. Somlo, et al., “Recombinant Human Thrombopoietin in Combination with Granulocyte Colony-Stimulating Factor . . . High-Dose Chemotherapy,” The American Society of Hematology, Blood, vol. 93, No. 9, pp. 2798-2806, May 1, 1999.
K. J. Neelis, et al., “The Efficacy of Single-Dose Administration of Thrombopoietin with Coadministration . . . Myelosuppressed Rhesus Monkeys,” The American So
Agur Zvia
Fleishmann Sarel
Skomorovski Kirill
Vardi Moshe
Moran Marjorie A.
Optimata Ltd.
LandOfFree
System and methods for optimized drug delivery and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with System and methods for optimized drug delivery and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and System and methods for optimized drug delivery and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3622470